证券代码：600718 证券简称：东软集团 公告编号：临 2025-064 东软集团股份有限公司 根据公司 2024 年股票期权激励计划，以及中国证券登记结算有限责任公司 上海分公司关于股票期权自主行权的相关规定，并结合公司 2025 年第三季度报 告披露计划等整体安排，现对公司 2024 年股票期权激励计划的自主行权时间进 行限制，具体情况如下： 一、公司股票期权已进入行权期的情况 公司 2024 年股票期权激励计划的第一个行权期（期权代码：1000000589） 为 2025 年 5 月 26 日-2026 年 3 月 6 日，目前处于行权阶段。 二、本次限制行权期为：2025 年 10 月 19 日至 2025 年 10 月 28 日，在此期 间，全部激励对象将限制行权。 三、公司将按照有关规定，及时向中国证券登记结算有限责任公司上海分公 司申请办理限制行权相关事宜。 特此公告。 关于股票期权激励计划限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担相应的法律责任。 东软集团股份有限公司董事会 二〇二五年十月 ...

证券代码：600718 证券简称：东软集团 公告编号：临 2025-063 东软集团股份有限公司 2024 年股票期权激励计划第一个行权期 2025 年第三季度自主行权结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次行权股票数量：公司 2024 年股票期权激励计划第一个行权期可行权 数量为 1,120.136 万份，可行权期限为 2025 年 5 月 26 日-2026 年 3 月 6 日（行 权日须为交易日）。2025 年第三季度，累计行权且完成登记 3,388,356 股，占本 期可行权数量的 30.25%。截至 2025 年 9 月 30 日，累计行权且完成登记 6,851,726 股，占本期可行权数量的 61.17%。 本次行权股票上市流通时间：公司本次采用自主行权模式，激励对象行 权所得股票可于行权日（T 日）后的第二个交易日（T+2）日上市交易。 一、2024 年股票期权激励计划已履行的决策程序和信息披露情况 于 2024 年 2 月 26 日召开的公司十届八次董事会审议通过了《关于<东软 ...

Core Viewpoint - The recent surge in fund returns has attracted significant attention, with notable performances from various funds, but the reality for retail investors may differ from the perceived opportunities [1][3]. Group 1: Fund Performance - In the first three quarters of the year, stock funds averaged a return of 28.18%, while mixed funds achieved 25.88%, with 97% of actively managed equity funds showing positive returns [3]. - Specific indices such as the Technology 50 Index and the Northern Stock Exchange 50 Index saw increases of 34% and 47.33% respectively, indicating a strong market performance [3]. Group 2: Retail Investor Behavior - Retail investors often enter the market at high points after media coverage, leading to losses when they sell during corrections [3][12]. - The tendency to follow trends without prior research results in missed opportunities, as institutional investors typically enter positions well before retail investors notice [3][12]. Group 3: Institutional Investment Insights - The concept of "institutional inventory" reflects the level of institutional engagement in stocks, with sustained involvement being a key driver of price increases [5][11]. - Stocks like "Cuiwei Co." demonstrated significant gains due to early institutional interest, while others like "Dongruan Group" failed to maintain momentum due to lack of sustained institutional support [5][9]. Group 4: Market Dynamics and Strategies - The market operates as a dynamic game, where the same positive news can yield different outcomes based on the prevailing market conditions [13]. - Retail investors are encouraged to develop a multi-dimensional observation system and validate their logic with data to better navigate market opportunities [12].

Group 1 - The core announcement indicates that Neusoft Corporation has won the bid for the medical insurance data service application project in Chuxiong Yi Autonomous Prefecture, with a bid amount of 1,950,000 [2][1] - The procurement was conducted by the Chuxiong Yi Autonomous Prefecture Medical Security Bureau, highlighting the company's involvement in public sector projects [2][1] - Neusoft Corporation has a significant investment footprint, having invested in 102 companies and participated in 43,389 bidding projects [1] Group 2 - The company holds a substantial intellectual property portfolio, including 428 trademark registrations, 2,251 patents, and 2,677 copyrights [1] - Neusoft Corporation has obtained 68 administrative licenses, indicating its compliance and operational capabilities within the industry [1]

Group 1 - The core viewpoint of the news is that Neusoft Group has launched its upgraded medical AI solution, "Tianyi Medical Health Intelligent Solution 2.0," showcasing its advancements in smart healthcare and addressing the challenges in AI implementation in the medical field [1][2] - The new solution focuses on six core scenarios: smart healthcare, smart services, smart management, smart grassroots, smart health, and urban health data space, enhancing the integration of medical business and data [1][2] - Neusoft's strategy emphasizes the transformation of AI and data into practical applications, aiming to meet the urgent needs for data governance, knowledge extraction, and scenario modeling in the healthcare system [2][3] Group 2 - Since early 2024, Neusoft has initiated a significant strategic transformation aimed at improving operational performance, focusing on AI and big data innovations [2][3] - The company has successfully implemented its smart healthcare products across various medical institutions, addressing critical pain points in clinical, research, and management areas, receiving positive feedback from users [2][3] - Neusoft has established over 300 invention patents and collaborated with more than 20 research partners, contributing to significant advancements in AI applications in healthcare [3] Group 3 - Neusoft Group has been selected as a designated supplier for a well-known domestic automotive manufacturer, providing intelligent cockpit domain controllers, with an estimated total supply amount of approximately 5.6 billion yuan over the product lifecycle [4][5] - The intelligent cockpit domain controller, based on the Qualcomm 8397 platform, integrates AI capabilities for enhanced user interaction through multi-modal recognition [5] - This partnership reflects Neusoft's long-term collaboration with the automotive manufacturer, reinforcing its competitive edge in the automotive electronics sector [5]

Core Insights - The Chinese healthcare information and digitalization market is experiencing significant challenges, with many companies facing business contraction and profit losses, while Eastsoft Group is strategically navigating this landscape to potentially reshape the market dynamics [1][2][4] Industry Overview - The healthcare IT sector is one of the hardest-hit areas, with a median revenue growth rate plummeting to -7.01% and a median net profit growth rate dropping to -26.09% for the first half of 2025 among 336 listed IT companies in China [2] - Factors contributing to this downturn include government budget tightening, delayed hospital budgets, and a shift in demand from large-scale construction to refined operations [2] Company Performance - Eastsoft Group's healthcare and social security business reported a slight revenue decline of 1.37%, while its subsidiary, Eastsoft Medical, achieved a modest revenue growth of approximately 4.01 million [2] - In contrast to the broader industry, where many companies are experiencing revenue declines of 20% to 30%, Eastsoft's performance indicates a potential reallocation of market share, positioning it as a likely beneficiary [2] Strategic Initiatives - Eastsoft is focusing on "defensive" strategies to maintain its core business while simultaneously launching targeted offensive strategies, particularly in smart hospital construction [4][5] - The company secured nearly 20 large contracts worth over 10 million each in the first half of 2025, showcasing its competitive strength in a contracting market [4] Technological Advancements - Eastsoft's AI strategy has evolved into a comprehensive, productized approach, exemplified by the launch of the "Tianyi" healthcare intelligent solution, which integrates eight categories of medical industry empowerment [6][7] - The rapid deployment of this solution in top-tier hospitals demonstrates Eastsoft's engineering capabilities and deep understanding of hospital pain points, allowing for quick market feedback [7] Partnerships and Collaborations - In March 2025, Eastsoft signed a comprehensive cooperation agreement with Huawei Technologies, aiming for deep collaboration in the healthcare sector, which is crucial for competing against major players like Alibaba and Tencent [9] Data Strategy - Eastsoft is transitioning from being a traditional software provider to a data value extractor and operator, as evidenced by its involvement in national and regional benchmark projects [10][11] - The company's participation in the construction of a national AI application pilot base for healthcare highlights its data technology capabilities at a national strategic level [10] Market Positioning - Eastsoft's dual strategy of leveraging AI and data is expected to create new growth avenues while establishing high technical and ecological barriers against competitors [12] - The company's ability to maintain cash flow and secure its foundational business while tapping into AI and data trends positions it as a market leader during challenging times [13] Future Outlook - Eastsoft's journey towards intelligent transformation is ongoing, with the need to demonstrate that its investments in AI and data can translate into effective commercial products and sustainable service revenues [14] - The company aims to become a true industry benchmark that defines standards, leads industry direction, and achieves sustainable development in the Chinese healthcare information sector [14]

Core Insights - The core point of the news is that Neusoft Corporation has won a bid for the upgrade of the drug and medical consumables procurement management subsystem as part of the third phase of the Liaoning Province Medical Security Bureau's medical insurance information platform construction project [1][2]. Group 1: Company Information - Neusoft Corporation has invested in a total of 102 companies and participated in 43,389 bidding projects [1]. - The company holds 428 trademark registrations, 2,251 patents, and 2,677 copyrights [1]. - Neusoft Corporation has obtained 68 administrative licenses [1]. Group 2: Project Details - The procurement was conducted by the Liaoning Province Medical Security Bureau [2]. - The bid amount won by Neusoft Corporation is 7,430,000 [2]. - The announcement date of the project is September 25, 2025 [2].

Core Insights - Data is recognized as the fifth production factor, characterized by non-competition, replicability, and unlimited growth potential, making its value extraction process more complex than traditional production factors [1] - The development of the data factor market relies heavily on a clear policy framework and implementation pathways, with local data trading institutions and data merchants emerging as key drivers [1] - The establishment of a robust ecosystem for data supply and usage is essential to achieve the goals of effective data flow and security [1] Group 1: Industry Overview - The data factor market is currently in a critical phase driven by policy and practical exploration, with the establishment of the National Data Bureau marking a significant step towards a unified national data market [19][20] - By 2025, the market size is projected to exceed 200 billion, with a compound annual growth rate of over 25% [23] - The construction of a complete national data circulation system is planned over the next five years, aiming to empower the real economy and stimulate growth [27] Group 2: Evaluation of Service Providers - The selection of "Outstanding Service Providers in the Data Factor Industry" is based on comprehensive evaluations by iResearch and industry experts, focusing on the capabilities of data developers, operators, and IT technology providers [2][4] - The evaluation model includes four core dimensions: industry depth, product and technology capabilities, service capabilities, and ecosystem capabilities [4] Group 3: Case Studies and Applications - Neusoft's City Data Value Empowerment Platform integrates data to enhance urban services in health, employment, and smart governance, creating a comprehensive service ecosystem [11][12] - The "Fujian Health Public Service Operation Platform" aims to provide a full lifecycle service system, while the "City Human Resources Development Platform" connects various stakeholders to promote employment and training [15] Group 4: Future Directions - The focus on high-quality data sets and specialized intelligent entities is expected to become mainstream, with ecosystem co-construction and scenario-building capabilities as core competitive advantages [20] - The establishment of a "trusted data space" is crucial for providing diverse data product choices to cross-domain consumers [25] - The industry faces challenges such as an incomplete pricing system and compliance barriers, which need to be addressed to facilitate the free flow of data in the market [31][28]

Meeting Overview - The second extraordinary general meeting of shareholders was held on September 24, 2025, at Neusoft Software Park, Shenyang [2] - The meeting was conducted in compliance with the Company Law and the Articles of Association, utilizing both on-site and online voting methods [2] Attendance - All 9 current directors attended the meeting, with some participating via video [3] - All 5 current supervisors were present, with some also joining through video [4] - Key executives, including the Secretary of the Board and other senior vice presidents, attended the meeting, with some participating via video [4] Resolutions Passed - The following resolutions were approved: 1. Proposal to abolish the supervisory board and amend the Articles of Association [5] 2. Proposal to revise the Rules of Procedure for Shareholders' Meetings [5] 3. Proposal to revise the Rules of Procedure for Board Meetings [6] 4. Proposal to revise the Independent Director Work System [6] 5. Proposal to establish the Compensation Management System for Directors and Senior Management [6] 6. Proposal to revise the Fundraising Management System [6] 7. Proposal to establish the External Guarantee Management System [6] 8. Proposal to establish the Management System for Preventing Fund Occupation by Controlling Shareholders and Related Parties [6] Voting Results - The first three proposals received special resolutions, passing with over two-thirds of the valid voting shares [6] Legal Verification - The meeting was witnessed by lawyers from Liaoning Qinglian Law Firm, confirming that all procedures and resolutions complied with relevant laws and regulations [7]

— 1 — 关于东软集团股份有限公司 2025 年第二次临时股东大会 之 法律意见书 辽宁青联律师事务所 关于东软集团股份有限公司 2025 年第二次临时股东大会之法律意见书 致：东软集团股份有限公司 辽宁青联律师事务所（以下简称"本所"）受东软集团股份有限公司（以 下简称"公司"）委托，指派朱香冰律师、刘宏雨律师（以下简称"本所律 师"）出席公司 2025 年第二次临时股东大会。根据《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股东会规则》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》（以下简称"《规范指引第 1 号》"）《律师事务所从 事证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）等现 行有效的法律、法规、规章、规范性文件以及东软集团股份有限公司章程（以 下简称"《公司章程》"）《东软集团股份有限公司股东会议事规则》（以下 简称"《股东会议事规则》"）等有关规定，本所律师就本次会议的召集、召 开程序、现场出席会议人员资格、表决程序等相关事项进行见证，并发表法律 意见。 为出具本《法律意见书》，本所律师出 ...